Radiotherapy with or without temozolomide in elderly patients aged >= 70 years with glioblastoma


Creative Commons License

Metcalfe E., Karaoglanoglu O., Akyazici E.

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, vol.20, no.3, pp.251-255, 2016 (Journal Indexed in ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 3
  • Publication Date: 2016
  • Doi Number: 10.5114/wo.2016.61569
  • Title of Journal : WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY
  • Page Numbers: pp.251-255

Abstract

Introduction: Although the recommended optimal treatment of glioblastoma multiforme (GBM) is adjuvant chemoradiotherapy, trials in GBM have excluded patients older than 70 years. In this study, we aimed to assess overall survival (OS) and prognostic factors in elderly patients (>= 70 years) with newly diagnosed GBM treated with radiotherapy (RT) +/- concurrent/adjuvant temozolomide (TMZ).